Adult Immunization

These tips from a family physician on managing misinformation in the exam room can help reduce the spread of false and misleading narratives.

The Kaiser Family Foundation survey found a 10% drop in the proportion of adults who say MMR vaccination should be required for school attendance, and other "halo" effects.

Preliminary estimates showed relative bivalent booster dose vaccine effectiveness against XBB/XBB.1.5 for at least the first 3 months after vaccination.

The mRNA vaccine returned efficacy of 83.7% against RSV-associated lower respiratory tract disease defined by ≥2 symptoms and of 82.4% against disease defined by ≥3 symptoms.

Overall dyspnea was the most common symptom of long COVID in the first year after infection, according to the nationwide retrospective cohort study.

One study showed the boosters provide significant protection against hospitalization and ED care and the other found vaccine effectiveness of 84% in older adults.

The vaccination campaign in the US also has prevented more than 18 million hospitalizations and saved $1 trillion in medical costs, according to a modeling study.

The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for adults aged ≥60 years.

Confidence in vaccines is lower post-pandemic across all demographic groups and is not limited to traditional "anti-vaxxers," say authors of a new study.

The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.